

YNT-185

Chemical Properties


CAS No. : 1804978-81-1

Formula: C33H37N5O5S

Molecular Weight: 615.74

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	YNT-185 is a nonpeptide, selective agonist of the orexin type-2 receptor (OX2R), with EC50 values of 0.028 μ M for OX2R and 2.75 μ M for OX1R. Additionally, YNT-185 effectively alleviates symptoms of narcolepsy-cataplexy in mouse models.
Targets(IC50)	OX Receptor
In vivo	YNT-185 (20-40 mg/kg; i.p.) enhances alertness in mice. In a dose-dependent manner, YNT-185 (300 nmol; i.c.v.) significantly extends wakefulness for 3 hours and reduces non-rapid eye movement (NREM) sleep duration in wild-type mice but not in OXRDKO mice.[1]

Solubility Information

Solubility	DMSO: 62 mg/mL (100.69 mM),Sonication is recommended. H2O: Insoluble (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Corn Oil: 2.5 mg/mL (4.06 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6241 mL	8.1203 mL	16.2406 mL
5 mM	0.3248 mL	1.6241 mL	3.2481 mL
10 mM	0.1624 mL	0.812 mL	1.6241 mL
50 mM	0.0325 mL	0.1624 mL	0.3248 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Irukayama-Tomobe Y, et al. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. *Proc Natl Acad Sci U S A.* 2017;114(22):5731-5736.

Nagahara T, et al. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. *J Med Chem.* 2015; 58(20):7931-7937.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481